Found 553 articles
Achieved Oxbryta®(voxelotor)net revenues of $36.9millionwith more than 1,000new patient prescriptionsin the third quarter and net revenues of $82.5 millionthroughfirst nine months of 2020
Relievant Medsystems Announces $70M Financing to Accelerate U.S. Commercialization of Intracept Procedure
Financing to build on significant 2020 commercial momentum following the publication of 5-year data demonstrating the long-term clinical benefits of the Intracept Procedure
Alexion Pharmaceuticals, Inc. announced financial results for the third quarter of 2020. Total revenues in the third quarter were $1,588.7 million, a 26 percent increase compared to the same period in 2019.
10/16/2020Biopharma and life sciences companies bolster their leadership teams with these Movers & Shakers.
Meissa Vaccines Expands Leadership Team as Company Advances Intranasal RSV and COVID-19 Live Attenuated Vaccine Candidates
Vaccine manufacturing and regulatory expert and business development and strategy leader bring further expertise as company advances RSV vaccine candidate into Phase 2 and scales production of an intranasal COVID-19 vaccine candidate for clinical trials REDWOOD CITY, Calif.--( BUSINESS WIRE )-- Meissa Vaccines (“Meissa”), a biotechnology company developing vaccines to prevent viral respiratory infections, announced today the appointments of William
Alexion Receives FDA Approval for New Advanced Formulation of ULTOMIRIS® (ravulizumab-cwvz) with Significantly Reduced Infusion Time
Alexion Receives FDA Approval for New Advanced Formulation of ULTOMIRIS ® (ravulizumab-cwvz) with Significantly Reduced Infusion Time – New 100 mg/mL formulation will reduce infusion time by approximately 60 percent, lessening the burden on patients – – ULTOMIRIS is approved for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) – BOSTON--( BUSINESS WIRE )-- Alexion Pharmaceuticals, Inc.
Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced the appointment of Mike Ouimette as general counsel and corporate secretary of the company.
Bay Area Lyme Foundation, a leading sponsor of Lyme disease research in the US, announces the launch of the Ticktective podcast and video series.
ULTOMIRIS® (ravulizumab) Receives Approval in Japan for Atypical Hemolytic Uremic Syndrome (aHUS) in Adults and Children
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) approved ULTOMIRIS® (ravulizumab) for adults and children living with atypical hemolytic uremic syndrome (aHUS).
Alexion Receives CHMP Positive Opinion for New Advanced Formulation of ULTOMIRIS® (ravulizumab) with Significantly Reduced Infusion Time
Alexion Pharmaceuticals, Inc. announced that the Committee for Medicinal Products for Human Use has adopted a positive opinion, recommending marketing authorization in the European Union for a new 100 mg/mL intravenous advanced formulation of ULTOMIRIS®.
9/11/2020Biopharma and life sciences companies bolster their leadership teams and boards with these Movers & Shakers.
Olema Oncology, a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for women's cancers, today announced it has strengthened its executive team with the appointment of Shane Kovacs , M.B.A., as Chief Operating Officer/Chief Financial Officer, Kinney Horn as Chief Business O
Alexion Announces Upcoming Data Presentations at MSVirtual2020, the 8th Joint ACTRIMS – ECTRIMS Meeting
Alexion Announces Upcoming Data Presentations at MSVirtual2020, the 8th Joint ACTRIMS – ECTRIMS Meeting - Accepted abstracts include data assessing the long-term efficacy and safety of SOLIRIS ® (eculizumab) in neuromyelitis optica spectrum disorder (NMOSD) - - Data from 11 abstracts demonstrate Alexion’s commitment to continuing to advance the understanding of the burden of NMOSD for patients and the efficacy and safety of SOLIRIS in real-world sett
9/4/2020Biopharma and life science companies from across the globe strengthen their leadership teams and boards with these Movers & Shakers.
Ultragenyx Appoints Mardi C. Dier as Chief Financial OfficerMs. Dier will start in new role in November 2020
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it has appointed Mardi C. Dier as Executive Vice President and Chief Financial Officer (CFO), effective November 2, 2020.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it has appointed Ernie Meyer as Executive Vice President and Chief Human Resources Officer, effective September 1, 2020.
Prelude Therapeutics, a privately-held, clinical-stage precision oncology company, announced that it has completed a $50 million Series C financing round led by Prelude’s two existing institutional investors, including OrbiMed Advisors LLC, and a new investor, Fidelity Management & Research Company LLC.
Jacob Lemieux, MD, DPhil and Artem Rogovskyy, DVM, PhD Named Recipients of Bay Area Lyme Foundation's 2020 Emerging Leader Award
Bay Area Lyme Foundation, a leading sponsor of Lyme disease research in the U.S., announces the recipients of the 2020 Emerging Leader Awards, which are designed to support promising scientists who represent the future of Lyme disease-research leadership
Spark Therapeutics Deepens Drug Development Expertise in Hematology and Rare Disease with Appointment of Gallia G. Levy, M.D., Ph.D., as Chief Medical Officer
Spark Therapeutics, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, today announced the appointment of Gallia Levy, M.D., Ph.D., as chief medical officer. Dr. Levy will be responsible for strategic and operational leadership across all functions in the product development lifecycle, including setting the global developme
In October 2019, Alexion Pharmaceuticals snapped up Achillon Pharmaceuticals and its oral small molecule Factor D inhibitor program for a rare kidney disease for $930 million in cash. This week, the company shuttered the program following disappointing clinical data.